These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37523059)

  • 1. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.
    Garg R; Aggarwal M; Mohammed A; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
    Indian J Gastroenterol; 2023 Oct; 42(5):718-723. PubMed ID: 37523059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
    Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
    Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
    Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
    Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
    Louis E; Litkiewicz M; Agboton C; Armuzzi A
    United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients.
    Garg R; Aggarwal M; Butler R; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
    Dig Dis Sci; 2022 Jul; 67(7):3138-3147. PubMed ID: 34160735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
    Chugh R; Long MD; Jiang Y; Weaver KN; Beaulieu DB; Scherl EJ; Mahadevan U
    Am J Gastroenterol; 2024 Mar; 119(3):468-476. PubMed ID: 37796648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.
    Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U
    J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease.
    Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Inflamm Bowel Dis; 2022 Feb; 28(2):218-225. PubMed ID: 33847351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
    Yanai H; Kagramanova A; Knyazev O; Sabino J; Haenen S; Mantzaris GJ; Mountaki K; Armuzzi A; Pugliese D; Furfaro F; Fiorino G; Drobne D; Kurent T; Yassin S; Maharshak N; Castiglione F; de Sire R; Nardone OM; Farkas K; Molnar T; Krznaric Z; Brinar M; Chashkova E; Livne Margolin M; Kopylov U; Bezzio C; Bar-Gil Shitrit A; Lukas M; Chaparro M; Truyens M; Nancey S; Lobaton T; Gisbert JP; Saibeni S; Bacsúr P; Bossuyt P; Schulberg J; Hoentjen F; Viganò C; Palermo A; Torres J; Revés J; Karmiris K; Velegraki M; Savarino E; Markopoulos P; Tsironi E; Ellul P; Calviño Suárez C; Weisshof R; Ben-Hur D; Naftali T; Eriksson C; Koutroubakis IE; Foteinogiannopoulou K; Limdi JK; Liu E; Surís G; Calabrese E; Zorzi F; Filip R; Ribaldone DG; Snir Y; Goren I; Banai-Eran H; Broytman Y; Amir Barak H; Avni-Biron I; Ollech JE; Dotan I; Aharoni Golan M
    J Crohns Colitis; 2022 Dec; 16(12):1882-1892. PubMed ID: 35895074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease.
    Melotti L; Dussias NK; Salice M; Calabrese C; Baldoni M; Scaioli E; Belluzzi A; Mazzotta E; Gionchetti P; Rizzello F
    Dig Liver Dis; 2023 Feb; 55(2):230-234. PubMed ID: 35879185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data.
    Ertem FU; Rivers CR; Ghaffari AA; Watson AR; Tang G; Schwartz M; Johnston E; Barrie A; Harrison J; Dueker JM; Hartman D; Binion DG
    Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 38953641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
    Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
    Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
    Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
    BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
    Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
    Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
    Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
    BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.
    Gebeyehu GG; Fiske J; Liu E; Limdi JK; Broglio G; Selinger C; Razsanskaite V; Smith PJ; Flanagan PK; Subramanian S
    Dig Dis Sci; 2023 May; 68(5):1983-1994. PubMed ID: 36436155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn's disease in Europe: a retrospective observational study.
    Weisshof R; Vavricka SR; Pouillon L; Braegger F; Roset M; Bent-Ennakhil N; Ferrante M
    BMC Gastroenterol; 2023 Nov; 23(1):417. PubMed ID: 38030966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.
    Dulai PS; Singh S; Jiang X; Peerani F; Narula N; Chaudrey K; Whitehead D; Hudesman D; Lukin D; Swaminath A; Shmidt E; Wang S; Boland BS; Chang JT; Kane S; Siegel CA; Loftus EV; Sandborn WJ; Sands BE; Colombel JF
    Am J Gastroenterol; 2016 Aug; 111(8):1147-55. PubMed ID: 27296941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.